Central precocious puberty: From genetics to treatment

Rebecca Schneider Aguirre, Erica Eugster

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Central precocious puberty (CPP) results from early activation of the hypothalamic - pituitary -gonadal (HPG) axis and follows the same sequence as normal puberty. While many factors involved in pubertal initiation remain poorly understood, the kisspeptin system is known to play a key role. Currently, mutations in the kisspeptin system, MKRN3, and DLK1 have been identified in sporadic and familial cases of CPP. The diagnosis is based on physical exam findings indicating advancing puberty and on laboratory tests confirming central HPG axis activation. GnRH analogs are the mainstay of treatment and are used with the goal of height preservation. Newer extended release formulations continue to be developed. Currently there is no evidence of long-term complications associated with treatment. However, many areas remain to be explored such as targeted therapies and aspects of clinical management. Further investigation into psychological effects and additional data regarding long-term outcomes, particularly in males, is needed.

Original languageEnglish (US)
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Kisspeptins
Puberty
Gonadotropin-Releasing Hormone
Psychology
Mutation
Central Precocious Puberty
Therapeutics

Keywords

  • central precocious puberty
  • etiology
  • genetics
  • outcome
  • treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Central precocious puberty : From genetics to treatment. / Aguirre, Rebecca Schneider; Eugster, Erica.

In: Best Practice and Research: Clinical Endocrinology and Metabolism, 01.01.2018.

Research output: Contribution to journalArticle

@article{a498666751b346758e1b92a1d81b9d92,
title = "Central precocious puberty: From genetics to treatment",
abstract = "Central precocious puberty (CPP) results from early activation of the hypothalamic - pituitary -gonadal (HPG) axis and follows the same sequence as normal puberty. While many factors involved in pubertal initiation remain poorly understood, the kisspeptin system is known to play a key role. Currently, mutations in the kisspeptin system, MKRN3, and DLK1 have been identified in sporadic and familial cases of CPP. The diagnosis is based on physical exam findings indicating advancing puberty and on laboratory tests confirming central HPG axis activation. GnRH analogs are the mainstay of treatment and are used with the goal of height preservation. Newer extended release formulations continue to be developed. Currently there is no evidence of long-term complications associated with treatment. However, many areas remain to be explored such as targeted therapies and aspects of clinical management. Further investigation into psychological effects and additional data regarding long-term outcomes, particularly in males, is needed.",
keywords = "central precocious puberty, etiology, genetics, outcome, treatment",
author = "Aguirre, {Rebecca Schneider} and Erica Eugster",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.beem.2018.05.008",
language = "English (US)",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",

}

TY - JOUR

T1 - Central precocious puberty

T2 - From genetics to treatment

AU - Aguirre, Rebecca Schneider

AU - Eugster, Erica

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Central precocious puberty (CPP) results from early activation of the hypothalamic - pituitary -gonadal (HPG) axis and follows the same sequence as normal puberty. While many factors involved in pubertal initiation remain poorly understood, the kisspeptin system is known to play a key role. Currently, mutations in the kisspeptin system, MKRN3, and DLK1 have been identified in sporadic and familial cases of CPP. The diagnosis is based on physical exam findings indicating advancing puberty and on laboratory tests confirming central HPG axis activation. GnRH analogs are the mainstay of treatment and are used with the goal of height preservation. Newer extended release formulations continue to be developed. Currently there is no evidence of long-term complications associated with treatment. However, many areas remain to be explored such as targeted therapies and aspects of clinical management. Further investigation into psychological effects and additional data regarding long-term outcomes, particularly in males, is needed.

AB - Central precocious puberty (CPP) results from early activation of the hypothalamic - pituitary -gonadal (HPG) axis and follows the same sequence as normal puberty. While many factors involved in pubertal initiation remain poorly understood, the kisspeptin system is known to play a key role. Currently, mutations in the kisspeptin system, MKRN3, and DLK1 have been identified in sporadic and familial cases of CPP. The diagnosis is based on physical exam findings indicating advancing puberty and on laboratory tests confirming central HPG axis activation. GnRH analogs are the mainstay of treatment and are used with the goal of height preservation. Newer extended release formulations continue to be developed. Currently there is no evidence of long-term complications associated with treatment. However, many areas remain to be explored such as targeted therapies and aspects of clinical management. Further investigation into psychological effects and additional data regarding long-term outcomes, particularly in males, is needed.

KW - central precocious puberty

KW - etiology

KW - genetics

KW - outcome

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85048772564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048772564&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2018.05.008

DO - 10.1016/j.beem.2018.05.008

M3 - Article

C2 - 30086862

AN - SCOPUS:85048772564

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

ER -